

NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(b)

Subject: Notification Pursuant to 18 V.S.A. § 4637(b)

To the Office of the Attorney General of Vermont:

Genentech USA, Inc. hereby notifies the Attorney General of Vermont of the following new prescription drug, pursuant to 18 V.S.A. § 4637(b):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)
Rozlytrek 50 mg Oral Pellets	50242-0623-42	March 04, 2024	\$ 4676.36

Frances Baffoe-Harding State Government Programs Manager Genentech USA, Inc.